



FEP Medical Policy Manual

FEP 2.04.44 Genetic Testing for Familial Cutaneous Malignant Melanoma

Effective Policy Date: July 1, 2022

Original Policy Date: December 2011

Related Policies:

2.04.146 - Gene Expression Profiling for Cutaneous Melanoma

2.04.77 - Genetic Testing to Select Melanoma or Glioma Patients for Targeted Therapy

Genetic Testing for Familial Cutaneous Malignant Melanoma

Description

Description

Cutaneous melanoma is the third most common type of skin cancer, but the most lethal. Some cases of cutaneous malignant melanoma are familial. Potential genetic markers for this disease are being evaluated in affected individuals with a family history of the disease and in unaffected individuals in a high-risk family.

OBJECTIVE

The objective of this evidence review is to evaluate the clinical validity and clinical utility of genetic testing of individuals with or at high-risk for familial cutaneous malignant melanoma and to determine if its use improves the net health outcome.

POLICY STATEMENT

Genetic testing for genes associated with familial cutaneous malignant melanoma or associated with susceptibility to cutaneous malignant melanoma is considered **investigational**.

POLICY GUIDELINES

Genetics Nomenclature Update

The Human Genome Variation Society nomenclature is used to report information on variants found in DNA and serves as an international standard in DNA diagnostics. It is being implemented for genetic testing medical evidence review updates starting in 2017 (Table PG1). The Society's nomenclature is recommended by the Human Variome Project, the Human Genome Organisation, and by the Human Genome Variation Society itself.

The American College of Medical Genetics and Genomics and the Association for Molecular Pathology standards and guidelines for interpretation of sequence variants represent expert opinion from both organizations, in addition to the College of American Pathologists. These recommendations primarily apply to genetic tests used in clinical laboratories, including genotyping, single genes, panels, exomes, and genomes. Table PG2 shows the recommended standard terminology - "pathogenic," "likely pathogenic," "uncertain significance," "likely benign," and "benign" - to describe variants identified that cause Mendelian disorders.

Table PG1. Nomenclature to Report on Variants Found in DNA

Previous	Updated	Definition
Mutation	Disease-associated variant	Disease-associated change in the DNA sequence
	Variant	Change in the DNA sequence
	Familial variant	Disease-associated variant identified in a proband for use in subsequent targeted genetic testing in first-degree relatives

Table PG2. ACMG-AMP Standards and Guidelines for Variant Classification

Variant Classification	Definition
Pathogenic	Disease-causing change in the DNA sequence
Likely pathogenic	Likely disease-causing change in the DNA sequence
Variant of uncertain significance	Change in DNA sequence with uncertain effects on disease
Likely benign	Likely benign change in the DNA sequence
Benign	Benign change in the DNA sequence

ACMG: American College of Medical Genetics and Genomics; AMP: Association for Molecular Pathology.

Genetic Counseling

Experts recommend formal genetic counseling for patients who are at risk for inherited disorders and who wish to undergo genetic testing. Interpreting the results of genetic tests and understanding risk factors can be difficult for some patients; genetic counseling helps individuals understand the impact of genetic testing, including the possible effects the test results could have on the individual or their family members. It should be noted that genetic counseling may alter the utilization of genetic testing substantially and may reduce inappropriate testing; further genetic counseling should be performed by an individual with experience and expertise in genetic medicine and genetic testing methods.

BENEFIT APPLICATION

Experimental or investigational procedures, treatments, drugs, or devices are not covered (See General Exclusion Section of brochure).

Screening (other than the preventive services listed in the brochure) is not covered. Please see Section 6 General exclusions.

Benefits are available for specialized diagnostic genetic testing when it is medically necessary to diagnose and/or manage a patient's existing medical condition. Benefits are not provided for genetic panels when some or all of the tests included in the panel are not covered, are experimental or investigational, or are not medically necessary.

FDA REGULATORY STATUS

Clinical laboratories may develop and validate tests in-house and market them as a laboratory service; laboratory-developed tests must meet the general regulatory standards of the Clinical Laboratory Improvement Amendments (CLIA). Melaris (Myriad Genetics) and other *CDKN2A* tests are available under the auspices of the CLIA. Laboratories that offer laboratory-developed tests must be licensed by the CLIA for high-complexity testing. To date, the U.S. Food and Drug Administration has chosen not to require any regulatory review of this test.

RATIONALE

Summary of Evidence

For individuals who have cutaneous malignant melanoma and a family history of this disease who receive genetic testing for genes associated with familial cutaneous malignant melanoma, the evidence includes genetic association studies measuring prevalence of variants in certain genes among those with cutaneous malignant melanoma. Relevant outcomes are overall survival, disease-specific survival, test accuracy, and test validity. Limitations with clinical validity include difficulties with variant interpretations, variable penetrance of a given variant, and residual risk with a benign variant. Currently, management of melanoma patients, which involves surveillance and education on sun avoidance behaviors, does not change based on genetic variants identified in genes associated with familial cutaneous malignant melanoma; therefore, clinical utility is lacking. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

For individuals who are asymptomatic and in a family at high-risk of developing cutaneous malignant melanoma who receive genetic testing for genes associated with familial cutaneous malignant melanoma, the evidence includes genetic association studies correlating variants in certain genes and the risk of developing cutaneous malignant melanoma. Relevant outcomes are overall survival, disease-specific survival, test accuracy, and test validity. Limitations with clinical validity include difficulties with variant interpretations, variable penetrance of a given variant, and residual risk with a benign variant. Currently, management of patients considered high-risk for cutaneous malignant melanoma focuses on the reduction of sun exposure, use of sunscreens, vigilant cutaneous surveillance of pigmented lesions, and prompt biopsy of suspicious lesions. It is unclear how genetic testing for variants associated with increased risk of cutaneous malignant melanoma would alter these management recommendations; therefore, clinical utility is lacking. The evidence is insufficient to determine that the technology results in an improvement in the net health outcome.

SUPPLEMENTAL INFORMATION

Practice Guidelines and Position Statements

Guidelines or position statements will be considered for inclusion in 'Supplemental Information' if they were issued by, or jointly by, a US professional society, an international society with US representation, or National Institute for Health and Care Excellence (NICE). Priority will be given to guidelines that are informed by a systematic review, include strength of evidence ratings, and include a description of management of conflict of interest.

American Society of Clinical Oncology

In an American Society of Clinical Oncology (ASCO) publication, Kefford et al (2002) noted that the sensitivity and specificity of tests for *CDKN2A* variants are not fully known.⁴⁶ Because interpreting genetic tests is difficult and because test results do not alter patient management, ASCO recommended that *CDKN2A* genetic testing should be performed only in clinical trials, for several reasons. These include a low likelihood of finding disease-associated variants in known melanoma susceptibility genes, uncertainty about the functionality and phenotypic expression of the trait among disease-associated variant carriers, and lack of proven melanoma prevention and surveillance strategies. Additionally, it was noted that all individuals

with risk factors for cutaneous melanoma should follow programs of sun protection and skin surveillance, not just those considered high-risk due to family history.

In 2003,⁴⁷ and 2010,⁴⁸ ASCO issued policy statements on genetic and genomic testing for cancer susceptibility. Both statements recommended that, outside of a research setting, genetic testing for cancer susceptibility should only be offered when the following 3 criteria are met: (1) the individual being tested has a personal or family history suggestive of an underlying hereditary component; (2) the genetic test can be adequately interpreted; and (3) test results will guide diagnosis and management.

In 2010, ASCO updated its policy statement on genetic and genomic testing for cancer susceptibility.⁴⁸ ASCO recommended that "genetic tests with uncertain clinical utility, including genomic risk assessment, be administered in the context of clinical trials."

In 2015, ASCO commissioned another update to its policy statement on genetic and genomic testing for cancer susceptibility.⁴⁹ ASCO "affirms that it is sufficient for cancer risk assessment to evaluate genes of established clinical utility that are suggested by the patient's personal and/or family history."

American Academy of Dermatology

In 2019, the American Academy of Dermatology published guidelines for the care and management of primary cutaneous melanoma.⁵⁰ Referral for genetic counseling and possible germline genetic testing for select patients with cutaneous melanoma was recommended for consideration with a level IIC grade of evidence. The Work Group explained that "there is no strong evidence that genetic evaluation is either harmful or helpful." Criteria for cancer risk genetic counseling with possible multigene testing for patients with cutaneous melanoma include:

- A family history of invasive cutaneous melanoma or pancreatic cancer (≥3 affected members on 1 side of the family)
- Multiple primary invasive cutaneous melanomas (≥3), including 1 early-onset tumor (at age <45 years)
- A family history of mesothelioma, meningioma, and/or uveal melanoma and ≥1 melanocytic *BAP1*-mutated atypical intradermal tumor (MBAIT)
- ≥2 MBAITs

These 2019 guidelines are similar to standards previously established by the International Melanoma Genetics Consortium in 2009.⁵¹

National Comprehensive Cancer Network

Current (v.2.2022) National Comprehensive Cancer Network (NCCN) guidelines for cutaneous melanoma include the following follow-up recommendations:⁵²

- "Consider genetic counseling referral for *p16/CDKN2A* mutation [variant] testing in the presence of 3 or more invasive melanomas, or a mix of invasive melanoma, pancreatic cancer, and/or astrocytoma diagnoses in an individual or family."
- "Multigene panel testing that includes *CDKN2A* is also recommended for patients with invasive cutaneous melanoma who have a first-degree relative diagnosed with pancreatic cancer."
- "Testing for other genes that can harbor melanoma-predisposing mutations [e.g., *MC1R*, *CDK4*, *TERT*, *MITF*, *PTEN*, *BRCA2*, and *BAP1*] may be warranted."

Current (v.1.2022) NCCN guidelines for genetic/familial high-risk assessment in breast, ovarian, and pancreatic cancer state that general melanoma risk management (eg, annual full-body skin examination, minimizing ultraviolet light exposure) is appropriate for *CDKN2A* mutation carriers.⁵³

U.S. Preventive Services Task Force Recommendations

Not applicable.

Medicare National Coverage

There is no national coverage determination. In the absence of a national coverage determination, coverage decisions are left to the discretion of local Medicare carriers.

REFERENCES

1. Hayward NK. Genetics of melanoma predisposition. *Oncogene*. May 19 2003; 22(20): 3053-62. PMID 12789280
2. Kefford RF, Newton Bishop JA, Bergman W, et al. Counseling and DNA testing for individuals perceived to be genetically predisposed to melanoma: A consensus statement of the Melanoma Genetics Consortium. *J Clin Oncol*. Oct 1999; 17(10): 3245-51. PMID 10506626
3. Niendorf KB, Goggins W, Yang G, et al. MELPREDICT: a logistic regression model to estimate CDKN2A carrier probability. *J Med Genet*. Jun 2006; 43(6): 501-6. PMID 16169933
4. Wang W, Niendorf KB, Patel D, et al. Estimating CDKN2A carrier probability and personalizing cancer risk assessments in hereditary melanoma using MelaPRO. *Cancer Res*. Jan 15 2010; 70(2): 552-9. PMID 20068151
5. de Snoo FA, Bergman W, Gruis NA. Familial melanoma: a complex disorder leading to controversy on DNA testing. *Fam Cancer*. 2003; 2(2): 109-16. PMID 14574160
6. Casula M, Colombino M, Satta MP, et al. Factors predicting the occurrence of germline mutations in candidate genes among patients with cutaneous malignant melanoma from South Italy. *Eur J Cancer*. Jan 2007; 43(1): 137-43. PMID 17055252
7. Pho L, Grossman D, Leachman SA. Melanoma genetics: a review of genetic factors and clinical phenotypes in familial melanoma. *Curr Opin Oncol*. Mar 2006; 18(2): 173-9. PMID 16462187
8. Ward KA, Lazovich D, Hordinsky MK. Germline melanoma susceptibility and prognostic genes: a review of the literature. *J Am Acad Dermatol*. Nov 2012; 67(5): 1055-67. PMID 22583682
9. Marzuka-Alcala A, Gabree MJ, Tsao H. Melanoma susceptibility genes and risk assessment. *Methods Mol Biol*. 2014; 1102: 381-93. PMID 24258989
10. Badenas C, Aguilera P, Puig-Butille JA, et al. Genetic counseling in melanoma. *Dermatol Ther*. Sep-Oct 2012; 25(5): 397-402. PMID 23046018
11. Delaunay J, Martin L, Bressac-de Paillerets B, et al. Improvement of Genetic Testing for Cutaneous Melanoma in Countries With Low to Moderate Incidence: The Rule of 2 vs the Rule of 3. *JAMA Dermatol*. Nov 01 2017; 153(11): 1122-1129. PMID 28903138
12. Bishop DT, Demenais F, Goldstein AM, et al. Geographical variation in the penetrance of CDKN2A mutations for melanoma. *J Natl Cancer Inst*. Jun 19 2002; 94(12): 894-903. PMID 12072543
13. Branstrom R, Kasparian NA, Affleck P, et al. Perceptions of genetic research and testing among members of families with an increased risk of malignant melanoma. *Eur J Cancer*. Nov 2012; 48(16): 3052-62. PMID 22726816
14. Harland M, Cust AE, Badenas C, et al. Prevalence and predictors of germline CDKN2A mutations for melanoma cases from Australia, Spain and the United Kingdom. *Hered Cancer Clin Pract*. 2014; 12(1): 20. PMID 25780468
15. Potrony M, Puig-Butille JA, Aguilera P, et al. Increased prevalence of lung, breast, and pancreatic cancers in addition to melanoma risk in families bearing the cyclin-dependent kinase inhibitor 2A mutation: implications for genetic counseling. *J Am Acad Dermatol*. Nov 2014; 71(5): 888-95. PMID 25064638
16. Bruno W, Pastorino L, Ghorzo P, et al. Multiple primary melanomas (MPMs) and criteria for genetic assessment: MultiMEL, a multicenter study of the Italian Melanoma Intergroup. *J Am Acad Dermatol*. Feb 2016; 74(2): 325-32. PMID 26775776
17. Di Lorenzo S, Fanale D, Corradino B, et al. Absence of germline CDKN2A mutation in Sicilian patients with familial malignant melanoma: Could it be a population-specific genetic signature?. *Cancer Biol Ther*. 2016; 17(1): 83-90. PMID 26650572
18. Mangas C, Potrony M, Mainetti C, et al. Genetic susceptibility to cutaneous melanoma in southern Switzerland: role of CDKN2A, MC1R and MITF. *Br J Dermatol*. Nov 2016; 175(5): 1030-1037. PMID 27473757
19. Puig S, Potrony M, Cuellar F, et al. Characterization of individuals at high risk of developing melanoma in Latin America: bases for genetic counseling in melanoma. *Genet Med*. Jul 2016; 18(7): 727-36. PMID 26681309
20. Artomov M, Stratigos AJ, Kim I, et al. Rare Variant, Gene-Based Association Study of Hereditary Melanoma Using Whole-Exome Sequencing. *J Natl Cancer Inst*. Dec 01 2017; 109(12). PMID 29522175
21. Gironi LC, Colombo E, Pasini B, et al. Melanoma-prone families: new evidence of distinctive clinical and histological features of melanomas in CDKN2A mutation carriers. *Arch Dermatol Res*. Dec 2018; 310(10): 769-784. PMID 30218143
22. De Simone P, Bottillo I, Valiante M, et al. A Single Center Retrospective Review of Patients from Central Italy Tested for Melanoma Predisposition Genes. *Int J Mol Sci*. Dec 11 2020; 21(24). PMID 33322357
23. Pissa M, Helkkula T, Appelqvist F, et al. CDKN2A genetic testing in melanoma-prone families in Sweden in the years 2015-2020: implications for novel national recommendations. *Acta Oncol*. Jul 2021; 60(7): 888-896. PMID 33945383
24. Ghorzo P, Bonelli L, Pastorino L, et al. MC1R variation and melanoma risk in relation to host/clinical and environmental factors in CDKN2A positive and negative melanoma patients. *Exp Dermatol*. Sep 2012; 21(9): 718-20. PMID 22804906
25. Kanetsky PA, Panossian S, Elder DE, et al. Does MC1R genotype convey information about melanoma risk beyond risk phenotypes?. *Cancer*. May 15 2010; 116(10): 2416-28. PMID 20301115
26. Ibarrola-Villava M, Hu HH, Guedj M, et al. MC1R, SLC45A2 and TYR genetic variants involved in melanoma susceptibility in southern European populations: results from a meta-analysis. *Eur J Cancer*. Sep 2012; 48(14): 2183-91. PMID 22464347
27. Cust AE, Goumas C, Holland EA, et al. MC1R genotypes and risk of melanoma before age 40 years: a population-based case-control-family study. *Int J Cancer*. Aug 01 2012; 131(3): E269-81. PMID 22095472
28. Cust AE, Drummond M, Kanetsky PA, et al. Assessing the Incremental Contribution of Common Genomic Variants to Melanoma Risk Prediction in Two Population-Based Studies. *J Invest Dermatol*. Dec 2018; 138(12): 2617-2624. PMID 29890168
29. Chatzinasiou F, Lill CM, Kypreou K, et al. Comprehensive field synopsis and systematic meta-analyses of genetic association studies in cutaneous melanoma. *J Natl Cancer Inst*. Aug 17 2011; 103(16): 1227-35. PMID 21693730
30. Williams PF, Olsen CM, Hayward NK, et al. Melanocortin 1 receptor and risk of cutaneous melanoma: a meta-analysis and estimates of population burden. *Int J Cancer*. Oct 01 2011; 129(7): 1730-40. PMID 21128237

31. Goldstein AM, Chaudru V, Ghiorzo P, et al. Cutaneous phenotype and MC1R variants as modifying factors for the development of melanoma in CDKN2A G101W mutation carriers from 4 countries. *Int J Cancer*. Aug 15 2007; 121(4): 825-31. PMID 17397031
32. Yang XR, Pfeiffer RM, Wheeler W, et al. Identification of modifier genes for cutaneous malignant melanoma in melanoma-prone families with and without CDKN2A mutations. *Int J Cancer*. Dec 15 2009; 125(12): 2912-7. PMID 19626699
33. Puntervoll HE, Yang XR, Vetti HH, et al. Melanoma prone families with CDK4 germline mutation: phenotypic profile and associations with MC1R variants. *J Med Genet*. Apr 2013; 50(4): 264-70. PMID 23384855
34. Primiero CA, Yanes T, Finnane A, et al. A Systematic Review on the Impact of Genetic Testing for Familial Melanoma I: Primary and Secondary Preventative Behaviours. *Dermatology*. 2021; 237(5): 806-815. PMID 33588421
35. Primiero CA, Yanes T, Finnane A, et al. A Systematic Review on the Impact of Genetic Testing for Familial Melanoma II: Psychosocial Outcomes and Attitudes. *Dermatology*. 2021; 237(5): 816-826. PMID 33508831
36. Aspinwall LG, Leaf SL, Dola ER, et al. CDKN2A/p16 genetic test reporting improves early detection intentions and practices in high-risk melanoma families. *Cancer Epidemiol Biomarkers Prev*. Jun 2008; 17(6): 1510-9. PMID 18559569
37. Aspinwall LG, Taber JM, Leaf SL, et al. Genetic testing for hereditary melanoma and pancreatic cancer: a longitudinal study of psychological outcome. *Psychooncology*. Feb 2013; 22(2): 276-89. PMID 23382133
38. Aspinwall LG, Taber JM, Leaf SL, et al. Melanoma genetic counseling and test reporting improve screening adherence among unaffected carriers 2 years later. *Cancer Epidemiol Biomarkers Prev*. Oct 2013; 22(10): 1687-97. PMID 23950214
39. Borroni RG, Manganoni AM, Grassi S, et al. Genetic counselling and high-penetrance susceptibility gene analysis reveal the novel CDKN2A p.D84V (c.251A T) mutation in melanoma-prone families from Italy. *Melanoma Res*. Apr 2017; 27(2): 97-103. PMID 28060055
40. Aspinwall LG, Stump TK, Taber JM, et al. Genetic test reporting of CDKN2A provides informational and motivational benefits for managing melanoma risk. *Transl Behav Med*. Jan 29 2018; 8(1): 29-43. PMID 29385581
41. Stump TK, Aspinwall LG, Kohlmann W, et al. Genetic Test Reporting and Counseling for Melanoma Risk in Minors May Improve Sun Protection Without Inducing Distress. *J Genet Couns*. Aug 2018; 27(4): 955-967. PMID 29349527
42. Stump TK, Aspinwall LG, Drummond DM, et al. CDKN2A testing and genetic counseling promote reductions in objectively measured sun exposure one year later. *Genet Med*. Jan 2020; 22(1): 26-34. PMID 31371819
43. van der Rhee JI, de Snoo FA, Vasen HFA, et al. Effectiveness and causes for failure of surveillance of CDKN2A-mutated melanoma families. *J Am Acad Dermatol*. Aug 2011; 65(2): 289-296. PMID 21570154
44. van der Rhee JI, Boonk SE, Putter H, et al. Surveillance of second-degree relatives from melanoma families with a CDKN2A germline mutation. *Cancer Epidemiol Biomarkers Prev*. Oct 2013; 22(10): 1771-7. PMID 23897584
45. Dalmasso B, Pastorino L, Ciccarese G, et al. CDKN2A germline mutations are not associated with poor survival in an Italian cohort of melanoma patients. *J Am Acad Dermatol*. May 2019; 80(5): 1263-1271. PMID 30274933
46. Kefford R. Clinical approach to genetic risk for melanoma. In: Perry M, ed. *American Society of Clinical Oncology Educational Book*. Baltimore: Lippincott Williams and Wilkins; 2002:436-445.
47. American Society of Clinical Oncology. American Society of Clinical Oncology policy statement update: genetic testing for cancer susceptibility. *J Clin Oncol*. Jun 15 2003; 21(12): 2397-406. PMID 12692171
48. Robson ME, Storm CD, Weitzel J, et al. American Society of Clinical Oncology policy statement update: genetic and genomic testing for cancer susceptibility. *J Clin Oncol*. Feb 10 2010; 28(5): 893-901. PMID 20065170
49. Robson ME, Bradbury AR, Arun B, et al. American Society of Clinical Oncology Policy Statement Update: Genetic and Genomic Testing for Cancer Susceptibility. *J Clin Oncol*. Nov 01 2015; 33(31): 3660-7. PMID 26324357
50. Swetter SM, Tsao H, Bichakjian CK, et al. Guidelines of care for the management of primary cutaneous melanoma. *J Am Acad Dermatol*. Jan 2019; 80(1): 208-250. PMID 30392755
51. Leachman SA, Carucci J, Kohlmann W, et al. Selection criteria for genetic assessment of patients with familial melanoma. *J Am Acad Dermatol*. Oct 2009; 61(4): 677.e1-14. PMID 19751883
52. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Cutaneous Melanoma. Version 2.2022. https://www.nccn.org/professionals/physician_gls/pdf/cutaneous_melanoma.pdf. Accessed February 2, 2022.
53. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology: Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic Version 1.2022. https://www.nccn.org/professionals/physician_gls/pdf/genetics_bop.pdf. Accessed February 1, 2022.

POLICY HISTORY - THIS POLICY WAS APPROVED BY THE FEP® PHARMACY AND MEDICAL POLICY COMMITTEE ACCORDING TO THE HISTORY BELOW:

Date	Action	Description
December 2011	New policy	
June 2012	Replace policy	Policy statement changed to not medically necessary.
December 2013	Replace policy	Policy updated with literature review, References added and updated.
December 2014	Replace policy	Policy updated with literature review. References 3, 4, 7, 20, 27, 28, and 30 added. Policy statement changed from not medically necessary to investigational. Title revised to Genetic Testing for Familial Cutaneous Malignant Melanoma.
June 2017	Replace policy	Policy updated with literature search through January 25, 2017;reference 18 added; reference 34 and 35 updated. The policy is revised with updated genetics nomenclature. "Mutations€ changed to "variants€ in policy statement. Policy statement otherwise unchanged.
June 2018	Replace policy	Policy updated with literature search through January 8, 2018;references 28 and 34 added. Policy statement unchanged.
June 2019	Replace policy	Policy updated with literature search through February 14, 2019; references added. Policy statement unchanged.
June 2020	Replace policy	Policy updated with literature search through January 2, 2020; references added. Policy statement unchanged.
June 2021	Replace policy	Policy updated with literature search through December 13, 2020; references added. Policy statement unchanged.
June 2022	Replace policy	Policy updated with literature search through February 2, 2022; references added. Policy statement unchanged.

The policies contained in the FEP Medical Policy Manual are developed to assist in administering contractual benefits and do not constitute medical advice. They are not intended to replace or substitute for the independent medical judgment of a practitioner or other health care professional in the treatment of an individual member. The Blue Cross and Blue Shield Association does not intend by the FEP Medical Policy Manual, or by any particular medical policy, to recommend, advocate, encourage or discourage any particular medical technologies. Medical decisions relative to medical technologies are to be made strictly by members/patients in consultation with their health care providers. The conclusion that a particular service or supply is medically necessary does not constitute a representation or warranty that the Blue Cross and Blue Shield Service Benefit Plan covers (or pays for) this service or supply for a particular member.